M. Lichtenfels, “What happens in residual disease after neoadjuvant chemotherapy? Efficacy of a novel in vitro breast cancer chemoresistance platform to demonstrate high resistance to drugs”, MAST, vol. 33, no. suppl.1, Mar. 2026.